Literature DB >> 15660576

Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure.

Kamyar Kalantar-Zadeh1, Rajnish Mehrotra, Denis Fouque, Joel D Kopple.   

Abstract

Metabolic acidosis, a common condition in patients with renal failure, may be linked to protein-energy malnutrition (PEM) and inflammation, together also known as malnutrition-inflammation complex syndrome (MICS). Methods of serum bicarbonate measurement may misrepresent the true bicarbonate level, since the total serum carbon dioxide measurement usually overestimates the serum bicarbonate concentration. Moreover, the air transportation of blood samples to distant laboratories may lead to erroneous readings. In patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD), a significant number of endocrine, musculoskeletal, and metabolic abnormalities are believed to result from acidemia. Metabolic acidosis may be related to PEM and MICS due to an increased protein catabolism, decreased protein synthesis, endocrine abnormalities including insulin resistance, decreased serum leptin level, and inflammation among individuals with renal failure. Evidence suggests that the catabolic effects of metabolic acidosis may result from an increased activity of the adenosine triphosphate (ATP)-dependent ubiquitin-proteasome and branched-chain keto acid dehydrogenase. In contrast to the metabolic studies, many epidemiologic studies in maintenance dialysis patients have indicated a paradoxically inverse association between mildly decreased serum bicarbonate and improved markers of protein-energy nutritional state. Hence metabolic acidosis may be considered as yet another element of the reverse epidemiology in ESRD patients. Interventional studies have yielded inconsistent results in CKD and ESRD patients, although in peritoneal dialysis patients, mitigating acidemia appears to more consistently improve nutritional status and reduce hospitalizations. Large-scale, prospective randomized interventional studies are needed to ascertain the potential benefits of correcting acidemia in malnourished and/or inflamed CKD and maintenance hemodialysis patients. Until then, all attempts should be made to adhere to the National Kidney Foundation Kidney Disease and Dialysis Outcome Quality Initiative guidelines to maintain a serum bicarbonate level in ESRD patients of at least 22 mEq/L.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15660576     DOI: 10.1111/j.0894-0959.2004.17606.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  58 in total

Review 1.  Current status of bicarbonate in CKD.

Authors:  Mirela Dobre; Mahboob Rahman; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2014-08-22       Impact factor: 10.121

Review 2.  Correction of chronic metabolic acidosis for chronic kidney disease patients.

Authors:  P Roderick; N S Willis; S Blakeley; C Jones; C Tomson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

3.  Effect of age and dialysis vintage on obesity paradox in long-term hemodialysis patients.

Authors:  Tania Vashistha; Rajnish Mehrotra; Jongha Park; Elani Streja; Ramnath Dukkipati; Allen R Nissenson; Jennie Z Ma; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2013-10-09       Impact factor: 8.860

Review 4.  Measurement of insulin resistance in chronic kidney disease.

Authors:  Hien Pham; Kristina M Utzschneider; Ian H de Boer
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-11       Impact factor: 2.894

5.  Kt/V and nPNA in pediatric peritoneal dialysis: a clinical or a mathematical association?

Authors:  F Cano; M Azocar; G Cavada; A Delucchi; V Marin; E Rodriguez
Journal:  Pediatr Nephrol       Date:  2005-10-06       Impact factor: 3.714

6.  Oral bicarbonate: renoprotective in CKD?

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2010-01       Impact factor: 28.314

7.  Blood trace minerals concentrations and oxidative stress in patients with obstructive sleep apnea.

Authors:  P C Chen; C H Guo; C J Tseng; K C Wang; P J Liu
Journal:  J Nutr Health Aging       Date:  2013       Impact factor: 4.075

8.  Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Authors:  Markus Ketteler; Marianne Rix; Stanley Fan; Nicholas Pritchard; Ove Oestergaard; Scott Chasan-Taber; Jeremy Heaton; Ajay Duggal; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

9.  Bicarbonate supplementation slows progression of CKD and improves nutritional status.

Authors:  Ione de Brito-Ashurst; Mira Varagunam; Martin J Raftery; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

10.  A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

Authors:  Stanley Fan; Calum Ross; Sandip Mitra; Philip Kalra; Jeremy Heaton; John Hunter; Melissa Plone; Nick Pritchard
Journal:  Nephrol Dial Transplant       Date:  2009-08-07       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.